Literature DB >> 6315759

Plasma adrenocorticotropin, cortisol, and aldosterone responses to corticotropin-releasing factor: modulatory effect of basal cortisol levels.

A R Hermus, G F Pieters, A G Smals, T J Benraad, P W Kloppenborg.   

Abstract

Two hundred micrograms of corticotropin-releasing factor (CRF) were administered as an iv bolus injection to 10 normal subjects (5 men and 5 women). Mean plasma ACTH levels rose significantly (P less than 0.0005, by Friedman's nonparametric analysis of variance) from a basal value of 27 +/- 5 pg/ml (mean +/- SEM) to a peak value of 63 +/- 8 pg/ml 30 min after CRF administration. This ACTH response was followed by a rise in plasma mean cortisol levels (P less than 0.0005, by Friedman's test) from a baseline value of 12.3 +/- 1.4 micrograms/100 ml to a peak value of 21.0 +/- 0.7 micrograms/100 ml 60 min after CRF and a rise in mean plasma aldosterone levels from a basal value of 13 +/- 2 ng/100 ml to a peak value of 23 +/- 2 ng/100 ml. There was no significant difference between men and women in the responsiveness of ACTH, cortisol, and aldosterone to CRF administration. The individual basal cortisol levels were highly significantly and negatively correlated with the areas under the individual ACTH curves (r = -0.76; P less than 0.005, by Pearson's correlation test) and cortisol curves (r = -0.91; P less than 0.001, by Pearson's test). These data suggest a modulatory effect of physiological cortisol levels on the response of the pituitary-adrenal axis to CRF.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6315759     DOI: 10.1210/jcem-58-1-187

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Safety and side effects of human and ovine corticotropin-releasing hormone administration in man.

Authors:  M Nink; U Krause; H Lehnert; J Beyer
Journal:  Klin Wochenschr       Date:  1991-03-18

2.  Low-renin primary hypertension in a young patient treated with dexamethasone.

Authors:  A P Tommaselli; G De Simone; L Di Lorenzo; R Rossi; A Cocca; R Valentino; B Biondi; G Lombardi
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

3.  Enhancement of the ACTH response to human CRH by pretreatment with the antiglucocorticoid RU-486.

Authors:  A R Hermus; G F Pieters; G J Pesman; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Endocrine activity of the "silent" adrenocortical adenoma is uncovered by response to corticotropin-releasing hormone.

Authors:  J Hensen; M Buhl; V Bähr; W Oelkers
Journal:  Klin Wochenschr       Date:  1990-06-19

5.  Sex defines the age dependence of endogenous ACTH-cortisol dose responsiveness.

Authors:  Daniel M Keenan; Ferdinand Roelfsema; Bernard J Carroll; Ali Iranmanesh; Johannes D Veldhuis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-06-17       Impact factor: 3.619

6.  Antiserotonergic inhibition of calcitonin-induced increase of beta-endorphin, ACTH, and cortisol secretion.

Authors:  L Laurian; Z Oberman; E Hoerer; E Graf
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

7.  Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.

Authors:  R A Salata; D B Jarrett; J G Verbalis; A G Robinson
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

8.  Quadruple injection of hypothalamic peptides to evaluate pituitary function in normal subjects.

Authors:  K C Kaltenborn; W Jubiz
Journal:  West J Med       Date:  1985-01

9.  Kinetics and Interrelations of the Renin Aldosterone Response to Acute Psychosocial Stress: A Neglected Stress System.

Authors:  Angelina Gideon; Christine Sauter; Judy Fieres; Thilo Berger; Britta Renner; Petra H Wirtz
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.